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Abstract
The efficacy of highly active antiretroviral therapy (HAART) has led to an increase demand for therapeutic use,
thereby necessitating investigation into drug toxicity. This study was designed to investigate the in vivo effects of
HAART on sperm parameters and testicular oxidative stress in lean and obese rats. Wistar rats (males, n = 40,
weighing 180~200 g) were assigned randomly into 4 groups and treated accordingly for 16 weeks as follows:
Control (C): lean group fed with standard rat chow; Diet induced obesity (DIO): obese animals fed a high caloric
diet; C + ART: lean animals treated with HAART; DIO + ART: obese animals treated with HAART. An antiretro-
viral drug combination of Tenofovir, Emtricitabine and Efavirenz at a dose of 17, 26 and 50 mg/kg/day was
administered for the latter 6 weeks via jelly cube feeding. At the end of the experimental period, sperm analysis
was performed on sperm collected from the caudal epididymis, while the testis was homogenized for antioxidant
enzyme and lipid peroxidation assays. Results showed that HAART significantly decreased sperm motility
(p < 0.05) in both lean and obese animals, and viability (p < 0.05) in the DIO group. Testicular glutathione, cata-
lase and superoxide dismutase were significantly decreased (p < 0.05), while Thiobarbituric acid reactive sub-
stances (TBARS) levels were significantly increased (p < 0.05) when the DIO+ART group was compared to
Control group. Thus, the decreased sperm qualities associated with HAART might be as a result of increased tes-
ticular oxidative stress prominent in obese animals.
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INTRODUCTION
The human immunodeficiency virus/acquired immuno-
deficiency syndrome (HIV/AIDS) epidemic has emerged
as a major global challenge affecting all ages, races, and
sexes. Highly active antiretroviral therapy (HAART) is
considered the most effective treatment for individuals
with HIV-1 infection. This therapy is a combination of
two or more antiretroviral drugs, usually nucleoside/nucle-
otide reverse transcriptase inhibitors (NRTIs) and prote-
ase inhibitors (PIs) or non-nucleoside reverse transcriptase
inhibitors (NNRTIs). A first-line, anti-HIV, fixed drug com-
bination containing tenofovir (TDF), emtricitabine (FTC),
and efavirenz (EFV), which combines two NRTIs (TDF
and FTC) and an NNRTI (EFV), has been recommended
for the treatment of patients with HIV infection and has
resulted in superior outcomes compared with other fixed-
dose treatments (1).
Generally, HAART has been associated with a reduc-
tion in the morbidity and mortality attributable to HIV-
induced immune deficiency (2). With the advent of HAART,
there has been a dramatic improvement in overall progno-
sis, with appreciable impact on the management of HIV
infection, reduction in viral replication, and increased hope
of parenthood for HIV patients (3-5). HAART has also
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demonstrated remarkable success in reducing the overall
health care costs for people who are HIV-positive (6,7).
Despite the numerous beneficial effects of HAART,
studies have revealed a number of side effects, clinical
adverse events, and toxicities. Clinical adverse effects asso-
ciated with HAART include AIDS-related insulin resis-
tance, hyperglycemia, and gastrointestinal and lipodystrophy
symptoms (8,9), whereas the most common toxicity asso-
ciated with NRTIs and NNRTIs is hepatotoxicity, which is
usually due to damage to mitochondria (10,11).
HIV infection is most common among individuals of
reproductive age and approximately one-third of those af-
fected desire to raise children. Therefore, reproductive effects
have emerged as clinically important issues in patients with
HIV infection (5). Alterations in reproductive physiology
have been responsible for subfertility in women infected
with HIV-1 (5) and direct gonadal failure has been associ-
ated with HIV infection in both sexes. Little attention has
been paid to the effects of HAART on male gametes, but
relevant studies have indicated that HIV-1-infected men
undergoing HAART experience alterations in semen parame-
ters (12). However, another study showed no alterations in
semen parameters (13). In a prospective study, Van Leeu-
wen et al. (14) highlighted the adverse effects of HAART
on sperm motility. These were attributed to the damaging
effect of these treatments on the mitochondria, which are
the power houses of the cell and play important roles in
sperm motility. HAART has also been associated with a
reduction in ejaculate volume, increase in abnormal sperm
morphology, and reduced potential to fertilize an oocyte
(15,16). However, these findings are debatable because it
is difficult to separate the role of the HIV infection from
the effect of treatment. Animal studies indicated that four
weeks of treatment with nevirapine caused degeneration
of the seminiferous tubules, necrosis of the spermatids,
and defoliation of spermatocytes (17).
Obesity is a public health issue that affects both chil-
dren and adults (18). It has been associated with the com-
bination of an increasingly sedentary lifestyle and an
unfavorable diet. A study carried out on the epidemic of
obesity among HIV patients revealed that two-thirds of
HIV patients in the studied cohort were overweight or
obese, a proportion that is similar to that among healthy
people living without HIV infection. This indicated that
the obesity epidemic also involves the HIV population
(19).
Despite the growing knowledge of the effects of HAART
on male reproduction, there are contradictory findings
with respect to objective sperm functional tests and anti-
oxidant status and it is currently unclear if HAART has a
different impact in those who are obese. The availability
of the different classes and combinations of antiretroviral
drugs is a further cause of concern because it is presumed
that different drug combinations can possibly have dissim-
ilar effects on biological systems. To the best of our knowl-
edge, no study has investigated the effect of this specific,
first-line, anti-HIV fixed drug combination containing TDF,
FTC, and EFV on male reproductive parameters. The pres-
ent study was therefore designed to investigate the effect
of combining TDF, FTC, and EFV on male sperm param-
eters and testicular antioxidant status in lean and diet-
induced obese rats.
MATERIALS AND METHODS
Drugs. A generic tablet of Odimune®, containing 200
mg emtricitabine (FTC), 300 mg tenofovir disoproxil fuma-
rate (TDF), and 600 mg efavirenz (EFV) and produced by
CIPLA MEDPRO (PTY) LTD (South Africa), was pur-
chased from commercial sources.
Study design. Forty inbred male Wistar rats (180~
200 g) were used for this study. Animals were randomly
divided into 4 experimental groups (n = 10/group) with no
differences in body weight (BW) between the 4 groups
prior to onset of the experiment. They had free access to
food and water and were kept on a 12 hr day/night cycle in
an AAALAC (Association for the Assessment and Accredi-
tation of Laboratory Animal Care International) accredited
facility for 16 weeks. Obesity was induced and maintained
in animals by feeding them a high calorie diet (20). The
experimental groups were as follows: control (C), lean
group fed with standard rat chow; diet induced obesity
(DIO), obese animals fed a high caloric diet; C + ART,
lean animals treated with HAART; DIO + ART, obese ani-
mals treated with HAART. HAART administration com-
menced at week 10 and continued through week 16 of the
experimental period. Treatment consisted of a once daily,
fixed dose combination of TDF, FTC, and EFV. The drugs
were ground into a powder, weighed, and added to jelly
cubes of 1 mL volume. These were then administered ac-
cording to the BW of each rat. The untreated groups received
an equal volume of jelly cubes without the drug. Treat-
ment administration was conducted according to the Food
and Drug Administration (FDA) standards for human to
rat conversion, which was six times the dose for human per
kg for rat as follows: EFV, 50 mg/kg/day; FTC, 17 mg/kg/
day; and TDF, 26 mg/kg/day. At the end of week 16, ani-
mals were anaesthetized with pentobarbital (160 mg/kg)
until deep anesthesia was reached as evidenced by the lack
of a pedal reflex. They were then euthanized by exsangui-
nation before tissue collection for further analysis. The
study received ethical clearance (SU-ACUM13-00025) from
the committee for the ethical use of animals in research at
the Faculty of Medicine and Health Sciences, Stellen-
bosch University and conformed to the Guide for the Care
and Use of Laboratory Animals of the NIH (Publication
No. 85-23, revised 1996).
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Anthropometric measurements. The BW of the ani-
mals was monitored throughout the experimental period.
Blood was obtained via a tail prick and fasting blood glu-
cose levels were determined using a conventional glucom-
eter (Cipla MedPro, Bellville, South Africa). The visceral
fat mass, testes, and epididymes were excised, weighed,
and preserved appropriately.
Sperm analysis. The cauda epididymis of each rat was
placed in 5 mL of HAMS F10 supplemented with 3% BSA
(Roche Diagnostics GmbH Mannheim, Germany) and cut
into several fragments to allow the spermatozoa to swim
out from the epididymal lumen. Sperm analysis was car-
ried out on sperm suspensions obtained from the 4 groups.
The quality of sperm was assessed based on its viability,
motility, and velocity parameters. Sperm motility and veloc-
ity parameter analysis was performed with computer-aided
sperm analysis (CASA) using a Sperm Class Analyser
(SCA®; Microptic, Barcelona, Spain). A 2 µL sample was
loaded into a pre-warmed eight-chamber standard count
analysis slide (Leja products, GN Nieuw-Vennep, The
Netherlands) at 37oC and analyzed. The system analyzed
the total motility and velocity parameters, including curvi-
linear velocity (VCL), straight line velocity (VSL), average
path velocity (VAP), amplitude of lateral head displace-
ment (ALH), and beat cross-frequency (BCF). Sperm via-
bility was determined using the eosin (EO) dye exclusion
test. Briefly, the sperm suspension was mixed thoroughly
and 10 µL of the suspension was mixed with 20 µL of
eosin and 30 µL of nigrosin dye. A thin smear was pre-
pared after 1 min, allowed to air-dry, and coverslipped.
The number of viable sperm was determined after the
counting of 100 spermatozoa (in duplicate) at × 100 mag-
nification under oil immersion in a blinded fashion (21).
The live spermatozoa were unstained and the dead sperm
were stained red, thereby indicating a damaged membrane.
Results were expressed as % viable cells.
Biochemical assays.
• Glutathione (GSH) status analysis: The testicular
total GSH was measured according to the method described
by Asensi et al (22). Briefly, testicular tissue samples were
homogenized (1 : 10) in 15% (w/v) trichloroacetic acid
containing 1 mM EDTA for GSH determination and in 6%
(v/v) perchloric acid containing freshly prepared 3 mM 1-
methyl-2-vinylpyridinium and 1 mM ethylenediaminete-
traacetic acid for GSH determination on ice. After centrif-
ugation at 10,000 g for 10 min, 50 µL of supernatant (tes-
ticular homogenate) was added to 50 µL of GSH reductase
(1 U) and 50 µL of 0.3 mM 5,5'-dithiobis-2-nitrobenzoic
acid. The reaction was initiated by the addition of 1 mM
NADPH to a final volume of 200 µL. The change in absor-
bance was monitored at 410 nm for 5 min and levels were
calculated using pure GSH as the standard.
• Superoxide dismutase: The activity of testicular
superoxide dismutase (SOD) was determined according to
the method of Crosti et al (24). Briefly, the reaction mix-
ture in a 96-well plate consisted of 15 µL of sample, 170
µL of 0.1 mM DETAPAC in 50 mM sodium phosphate
buffer (pH 7.4), and 20 µL of 1.6 mM 6-hydroxydopamine,
which initiated the reaction. The reaction was measured at
490 nm for 4 min at 30 s intervals and SOD activity was
expressed as U/mg of protein.
• Catalase (CAT): CAT activity in the testicular homoge-
nates was determined using the method described by Aebi
(23). Briefly, 5 µL of sample and 170 µL of 50 mM potas-
sium phosphate (pH 7.0) were added to a clear 96-well
plate, followed by 50 µL of 0.1% hydrogen peroxide (H2O2)
in 50 mM potassium phosphate (pH 7.0) to initiate the reac-
tion. The rate of decomposition of H2O2 was measured at
240 nm for 2 min in 15 s intervals using a Multiskan Spec-
trum plate reader (Thermo Fisher Scientific, USA). CAT
activity (µmol H2O2 consumed/min/µg protein) was deter-
mined using the molar extinction coefficient of 43.6.
• Estimation of thiobarbituric acid reacting substances
(TBARS): Testicular lipid peroxidation products were esti-
mated by determining TBARS, a product of lipid oxida-
tion. TBARS were measured on a plate reader according
to a method modified from that of Khoschsorur et al (25).
Fifty microliters of testicular homogenates was mixed with
375 µL of 0.44 M H3PO4 and 125 µL of 42 mM aqueous
2-thiobarbituric acid, then 225 µL of distilled water was
added. The mixture was heated in boiling-water in a water
bath for 60 min. After cooling on ice, alkaline methanol
(5 mL + 45 mL 1 M NaOH) was added to the reaction
mixture in a 1 : 1 ratio. The samples were centrifuged for
3 min and absorbance was read at 535 nm using a micro
plate reader.
Statistical analyses. The data are presented as mean ±
SEM and were analyzed using one-way analysis of vari-
ance (ANOVA) followed by Bonferroni’s multiple com-
parison test, which was performed using GraphPad Prism
version 5.00 for Windows (GraphPad Software, San Diego,
CA, USA). A result of p < 0.05 was considered statistically
significant.
RESULTS
Effects of HAART on BW, organ weight, peritoneal fat,
and plasma glucose. The BW of all animals increased
significantly during the research period; however, all ani-
mals in the DIO group gained significantly more weight
than their counterparts (Table 1). The final BW of the DIO
group was significantly higher than that of the C group
(436.6 g ± 15.11 vs. 347.40 g ± 12.10; p < 0.05) and the
final BW of the animals in the DIO+ART group was sig-
nificantly higher than that of the animals in the C + ART
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group (440.70 g ± 11.10 vs. 350.40 g ± 13.09; p < 0.05) and
that of the C group (440.70 g ± 11.10 vs. 347.40 g ±
12.10; p < 0.05). HAART treatment did not induce any
significant BW changes in the respective dietary groups;
however, there was a comparable BW gain and percent-
age BW gain in all experimental groups.
Visceral fat mass was higher in the DIO group than in
the C group (25.84 g ± 2.81 vs. 13.14 g ± 2.10; p < 0.05).
Visceral fat mass was also higher in the DIO + ART group
than in the C + ART group (27.29 g ± 3.10 vs 12.01 g ±
2.32; p < 0.05). The differences in visceral fat mass in the
C vs. C + ART and in the DIO vs. DIO + ART were com-
parable (Table 1).
Treatment with HAART resulted in significantly reduced
testicular tissue of obese animals in the DIO + ART group
compared with that in the DIO group (2.88 g ± 0.10 vs.
2.97 ± 0.11, p < 0.05). A decrease in testicular weight was
also observed between obese and lean animals (Table 2).
No differences were observed in epididymal weight or rel-
ative testicular and epididymal weight. Similarly, no dif-
ferences were observed in the fasting blood glucose levels
among any of the four groups (Table 2).
Effect of HAART on sperm parameters. The viabil-
ity of spermatozoa significantly decreased after obese ani-
mals received HAART treatment (DIO vs. DIO + ART:
73.86 ± 6.26% vs. 52.43 ± 5.08%, p < 0.05). Obesity per
se also significantly reduced sperm viability, as indicated
by the comparison between the C and DIO groups (84.00 ±
7.32% vs. 73.86 ± 6.26%, p < 0.05) and that between the
C + ART and DIO + ART groups (83.29 ± 6.43% vs. 52.43 ±
5.08%, p < 0.05) (Table 3). The reported values regarding
the margin of change observed due to the combinations
and treatment indicated that the combination of obesity
and HAART negatively impacted the percentage of viable
cells (Table 3).
There was a significant decrease in sperm motility when
that from the C group was compared with that from the
Table 1. Body and visceral fat weights during the experimental period
Body weight Visceral fat
(g)Initial (g) Final (g) Absolute difference (g) Percentage change (%)
C 303.90 ± 9.67 347.40 ± 12.10 43.50 ± 6.05 14.31 ± 2.42 13.14 ± 2.10
DIO 390.50 ± 10.43* 436.60 ± 15.11* 46.10 ± 8.36 11.81 ± 5.64 25.84 ± 2.81*
C + ART 305.40 ± 11.32 350.40 ± 13.09 45.00 ± 5.76 14.74 ± 3.19 12.01 ± 2.32
DIO + ART 392.40 ± 8.10*+ 440.70 ± 11.10*+ 48.30 ± 5.06 12.31 ± 3.20 27.29 ± 3.10*+
Initial = weight prior to onset of HAART treatment (week 10), Final = weight after being on 6 weeks diet and HAART treatment (week
16), % difference = Absolute difference/Initial BW × 100.
Data are expressed as mean ± SEM (n = 10).
*p < 0.05: compared to C. +p < 0.05: compared to C + ART.
Table 2. Organ weight and plasma glucose levels of the experimental groups
Groups
Testicular
weight (g)
Epididymal
weight (g)
Relative testicular
weight (%)
Relative epididymal
weight (%)
Fasting glucose
(mmol/L)
C 3.37 ± 0.10 1.45 ± 0.05 0.97 ± 0.05 0.42 ± 0.03 5.30 ± 0.80
DIO 2.97 ± 0.11* 1.39 ± 0.06 0.68 ± 0.07 0.32 ± 0.02 5.30 ± 0.91
C + ART 3.30 ± 0.09 1.31 ± 0.03 0.94 ± 0.04 0.37 ± 0.03 5.37 ± 0.81
DIO + ART 2.88 ± 0.10*+ 1.35 ± 0.03 0.65 ± 0.08 0.31 ± 0.02 5.38 ± 0.91
Relative testicular weight = Testicular weight/Body weight × 100, Relative epididymal weight = Epididymal weight/Body weight × 100.
Data are expressed as mean ± SEM (n = 10).
*p < 0.05: compared to C. +p < 0.05: compared to C + ART.
Table 3. Sperm analysis in the experimental groups
Groups Viability (%) Total motility (%) VCL (µm/s) VSL (µm/s) ALH (µm/s) BCF (Hz)
C 84.00 ± 7.32 82.14 ± 7.60 185.00 ± 10.09 47.88 ± 3.42 11.40 ± 1.23 3.60 ± 0.50
DIO 73.86 ± 6.26* 71.56 ± 6.81* 173.56 ± 14.42 45.61 ± 3.98 08.86 ± 1.10* 2.50 ± 0.23
C + ART 83.29 ± 6.43 63.01 ± 4.91* 176.23 ± 12.61 46.79 ± 4.89 06.38 ± 1.30* 1.65 ± 0.30*
DIO + ART 52.43 ± 5.08*#+ 50.23 ± 4.76*#+ 136.62 ± 10.76*#+ 41.85 ± 3.11* 04.22 ± 1.90*# 1.72 ± 0.43*#
VCL = curvilinear velocity; VSL = straight line velocity, ALH = amplitude of lateral head displacement; BCF = beat cross frequency. Data are
expressed as mean ± SEM (n = 10).
*p < 0.05: compared to C. #p < 0.05: compared to DIO. +p < 0.05: compared to C + ART.
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(38.67 ± 4.28 vs. 18.83 ± 1.85 µg/mg protein, p < 0.05)
(Fig. 1A). Similarly, SOD (7.92 ± 0.16 vs. 6.23 ± 0.23 µg/
mg protein, p < 0.05) and CAT (168.55 ± 4.61 vs. 112.80 ±
10.94 µg/mg protein, p < 0.05) activities also decreased in
only the obese animals after HAART treatment (Fig. 1B,
1C). HAART treatment had no effect on these two metal-
loprotein antioxidant enzymes in the lean animals. Lipid
peroxidation, as measured by the TBARS level, signifi-
cantly (p < 0.05) increased in the DIO + ART group com-
pared with that in the C + ART group (Fig. 1D) and in the
C group compared with that in the DIO group (2.06 ± 0.01
vs 2.22 ± 0.02 µmol/mg protein, p < 0.05).
DISCUSSION
The introduction of HAART in the management of HIV
has improved therapeutic outcomes by reducing mortality
and morbidity. However, this therapy has a number of
challenging pitfalls, probably due to associated drug-drug
interactions, organ specific toxicity, and non-adherence.
There is paucity of information in the literature regarding
the adverse effects of HAART on male reproductive func-
tion and the probable mechanisms underlying the harmful
reproductive effects. We report for the first time that
HAART consisting of TDF, FTC, and EFV has spermato-
toxic effects associated with elevated lipid peroxidation
products and concomitant reduction in testicular antioxi-
C + ART group (82.14 ± 7.60% vs. 63.01 ± 4.91%, p < 0.05)
and when that from the DIO group was compared with
that from the DIO + ART group (71.56 ± 6.81% vs. 50.23 ±
4.76%, p < 0.05). We also observed that obesity impaired
motility when the C group was compared with the DIO
group (82.14 ± 7.60% vs. 71.56 ± 6.81%, p < 0.05) and
the C + ART group was compared with the DIO + ART
group (63.01 ± 4.91% vs. 50.23 ± 4.76%, p < 0.05). Inter-
estingly, the greatest percentage reduction in motility was
observed when HAART treatment was combined with
obesity (Table 3).
Various kinematic and velocity parameters were also
affected by obesity (ALH), HAART alone (ALH, BCF),
and the combination of obesity and HAART (VCL, VSL,
ALH, BCF), as shown in Table 3.
Effects of HAART on oxidative stress. Administration
of HAART caused a significant decrease (p < 0.05) in tes-
ticular GSH concentration as indicated by the significant
difference between GSH levels in the C and C + ART
groups (74.50 ± 3.90 vs. 38.67 ± 4.28 µg/mg protein, p <
0.05) and that between the DIO and DIO + ART groups
(50.17 ± 4.18 vs. 18.83 ± 1.85 µg/mg protein, p < 0.05).
Obesity also reduced testicular GSH concentrations sig-
nificantly, based on the comparison between the C and
DIO groups (74.50 ± 3.9 vs. 50.17 ± 4.18 µg/mg protein,
p < 0.05) and the C + ART and DIO + ART groups
Fig. 1. (A) Glutathione concentration levels in testicular tissue of HAART-treated Wistar rats. (B) Superoxide dismutase activity lev-
els in testicular tissue of HAART-treated Wistar rats. (C) Catalase activity levels in testicular tissue of HAART-treated Wistar rats. (D)
Lipid peroxidation (TBARS) levels in testicular tissue of HAART-treated Wistar rats. Bars indicate the mean ± SEM (n = 10). *p < 0.05:
compared to C. #p < 0.05: compared to DIO. +p < 0.05: compared to C + ART.
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dant status in both lean and obese rats. It is well known
that oxidative stress results from the imbalances between
antioxidants and free radicals. The cells are generally pro-
tected from oxidative stress by enzymatic (CAT, SOD)
and non-enzymatic (GSH) complex antioxidant systems
(26). Oxidative stress has been reported to be one of the
most important causes of male infertility and has been
associated with altered sperm function and steroidogenic
capacity. It impairs the ability of LH to activate the ste-
roidogenic acute regulatory (StAR) protein-catalyzed trans-
port of cholesterol from the outer mitochondrial membrane
to the inner mitochondrial membrane, which is a rate-lim-
iting step in steroid biosynthesis (27).
The significant increase in final BW and visceral fat
mass observed in the DIO group was an indication that
obesity was successfully induced by the diet. Sperm motil-
ity and viability are important features of fertile spermato-
zoa. These attributes are dependent on an adequate energy
supply and a jealously-guarded polyunsaturated fatty acid
membrane susceptible to oxidative stress mediated dam-
age (28).
The results indicated that total sperm motility decreased
significantly in both groups of HAART-treated animals.
The observed decrease in sperm parameters in the DIO
group was similar to that in previous studies, which showed
that obesity was associated with reduced total sperm
motility in rats (29,30). In addition, our data indicated that
HAART caused decreased sperm motility because even in
lean mice, a decrease in motility was observed. However,
it is worth noting that the decrease in motility ascribed to
HAART was more pronounced in the obese group. An
earlier study also associated HAART, consisting of zid-
ovudine, lamivudine, and nevirapine, with reduced sperm
motility in rats (28), whereas TDF, when used in isola-
tion, was previously reported to have spermiostatic activ-
ity (31). The decrease in VCL, ALH, and BCF values of
spermatozoa observed in this study showed that HAART
adversely influenced the swimming pattern of spermato-
zoa and consequently had a negative effect on fertility
potential, whereas obesity aggravated the adverse effect.
In addition, it is important to note that these parameters
are markers of sperm vigor, cervical mucus penetration,
and effective rate of fertilization necessary as the sperm
travels through the female reproductive tract to fertilize
the oocyte (32,33). The decreases in VCL and BCF in the
DIO group treated with HAART correlated with the sig-
nificant reduction in sperm viability because these param-
eters have been linked with the viability of the sperm
(34,35).
The increased visceral fat in the DIO + ART group might
have also contributed to the adverse reproductive effects
observed in this group. Previous reports indicated that
increased fat deposition compromised the efficacy of ther-
moregulation, reduced the radiation of heat, increased the
generation of reactive oxygen species (ROS), and pro-
moted the development of oxidative stress in reproductive
organs, ultimately resulting in reduced sperm quality (36-
38). The observed increase in lipid peroxidation, evidenced
by an increase in the level of TBARS in the testicular tis-
sue, was similar to earlier findings that associated increased
oxidative stress with HIV treatment (39). The decrease in
GSH levels might have contributed to an increase in lipid
peroxidation because GSH is an antioxidant that reacts
directly with free radicals in non-enzymatic reactions and
protects cells against a variety of different ROS. Similarly,
the significant decrease in the activity of SOD and CAT in
the groups treated with HAART suggested an inability of
their testicular tissue to inactivate/dismutase O2
− and/or
eliminate H2O2, thereby leading to an accumulation of
these highly reactive radicals within the testicular tissue.
The possibility of depletion of CAT owing to an increase
in H2O2 as a result of a corresponding decrease in enzyme
activity during HAART metabolism cannot be ruled out.
The observed decrease in sperm parameters might have
been caused by the increased lipid peroxidation within the
testis because destruction of the structure of the lipid matrix
in the spermatozoa plasma membrane leads to loss of
intracellular ATP, resulting in decreased sperm motility
and viability. The decrease in testicular SOD activity may
have been a result of decreased de novo synthesis of
enzyme proteins or inactivation of these enzyme proteins,
leading to a decrease in function (40).
Lipid peroxidation of unsaturated fatty acids is often
used as an indicator of oxidative stress and oxidative dam-
age (41). The increased TBARS concentration might have
been due to a decreased production of antioxidants in the
HAART-treated rat tissues, thereby shifting the delicate
balance in favor of ROS and leading to a plethora of patho-
logic damage to sperm cells, including lipid peroxidation
and concomitant loss of function. This study further indi-
cated that down-regulation of antioxidant enzyme levels in
the treated rats was a mechanism by which HAART induced
infertility in the male rat, possibly because of mitochon-
drial damage caused by HAART, which is a source of oxi-
dative radicals, as was reported in other organs (10,11).
We therefore concluded that HAART altered sperm parame-
ters through increased testicular oxidative stress by de-
creasing the concentration and activity of antioxidants and
obesity, caused by a high calorie diet, exacerbated these
adverse effects. Further studies are recommended to eval-
uate to what extend these effects translate into infertility
and the potential of utilizing exogenous antioxidants, such
as such as Vitamin C or E, with HAART therapies.
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